Healthcare ❯ Pharmaceuticals ❯ Clinical Trials
Prostate Cancer Talzenna and Xtandi PADCEV™ Multiple Myeloma HER2-positive Gastroesophageal Adenocarcinoma
Stronger sales of newer cancer and immune therapies offset the Stelara decline, supporting a higher full-year view despite pricing concessions.
